BioSpace News Archive

Zomedica Corp. provided a business update and will be hosting a conference call.

biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance.

Apollomics Inc. (“Apollomics” or the “Company”) today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference on Thursday, January 18, 2024 at 11:00 a.m. ET.

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 18th, at 2:30 pm ET.

Shanghai Junshi Biosciences Co., Ltd announced the publication of results from the prespecified interim analysis for event-free survival in patients with stage III non-Small Cell Lung Cancer of NEOTORCH in theJournal of the American Medical Association.

Bayer will present new data across its prostate cancer portfolio at the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place January 25-27, 2024 in San Francisco, California.

Lichen striatus (LS), a skin condition manifesting as linear eruptions following Blaschko’s lines on the trunk or limbs of children, is often accompanied by hypopigmentation (loss of melanin or skin color).

CNS Pharmaceuticals, Inc. today announced completion of planned enrollment in its global potentially pivotal study evaluating Berubicin.

Neuvivo today announced the appointment of Dr. James Kovach, MD, JD, as its new Chief Medical Affairs Officer.

Better Therapeutics Inc. announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes, AspyreRx.